A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 15 Jan 2024
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Registrational
- Sponsors Amgen
- 09 Mar 2023 Status changed from active, no longer recruiting to completed.
- 09 Mar 2023 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 16 Jan 2023 This trial has been completed in Estonia , according to European Clinical Trials Database record.